Accelry Solutions for Enhancing Research Innovation: An Interactive Seminar


Speaker Bios

Andrew Buchanan - MedImmunne, UK
Andrew is a Senior Scientist and Team Leader at MedImmune in Antibody Discovery and Protein Engineering working on Oncology and CVGI therapeutic projects. He has 12 years experience in antibody and protein engineering and has contributed to the discovery of 7 candidate drugs that are currently in preclinical or clinical development. He is an inventor on MEDI578 as well as display technology patents. He has also developed the ribosome display platform to optimise therapeutic proteins for stability and expression as well as affinity. Before joining CAT, he was a postdoc at Monsanto. Andrew is a graduate of University of Oxford and has a PhD in molecular genetics from University of Bath.

Pekka Tiikkainen - Merz, Germany
Pekka did his PhD studies at University of Turku in Finland where he worked as a computational chemist in a cancer research group. During the graduate studies, he participated in cancer drug research projects and studied the performance and synergy of ligand-based virtual screening tools. Since January 2010, he is working as a cheminformatician in a drug repurposing team at Merz Pharmaceuticals in Frankfurt, Germany. At Merz, his main task has been to build up an informatics infrastructure for the team and perform drug target predictions.

Adel Laoui - Managing Director Life Science R&D Business Segment, Accelrys, US
Adel has more than 20 years of research and development experience in the Pharmaceutical/Healthcare industry. Adel’s expertise is derived from a career that has spanned the areas of pharmaceutical development, healthcare solutions and data analytics with his focus being on patient-centred and preventive population-based approach to deliver holistic care with the goal of enabling a more sustainable and cost effective quality of life for the patients and caregivers.

Adel has deep experience in leading both matrix-based organizations and R&D processes from target validation to lead identification, clinical optimization and to integrated healthcare solutions which will help drive Accelrys Life Science R&D segment business strategy forward. He holds a PhD. in Chemical Physics and Informatics from the University of Renee Descartes Medical School and an executive MBA in advanced finance, digital marketing and business strategy from Rutgers University.

Beyond work Adel is an active fan of Soccer and still a committed player in the adult competitive league in Princeton. He loves traveling across the four continents of America, Asia, Europe and Africa.

Stephen Pickett - GlaxoSmithKline, UK
Stephen studied for a degree in Chemistry at Keble College, Oxford. His PhD , under Prof. John Meurig Thomas at the Royal Institution of Great Britain, involved the study of the adsorption and diffusion of small molecules in zeolites using Monte Carlo and Molecular Dynamics methods. Postdoctoral studies followed at the Imperial Cancer Research Fund (now part of Cancer Research UK) with Prof Michael Sternberg, looking at various aspects of protein folding including the derivation of a scale for side-chain entropy. From the ICRF he took up his first position in the pharmaceutical industry, working for Rhone-Poulenc Rorer at Dagenham, UK. Seven years at RPR included a two-year posting to the French research site at Vitry-sur-Seine, Paris. Eighteen months were spent at the Roche research facility in Welwyn Garden City, UK before taking up his current position as a Group Leader in Computational Chemistry and Informatics at GlaxoSmithKline, Stevenage. Dr Pickett’s current interests include the computational chemistry and informatics aspects of fragment based drug discovery, high throughput screening, screening collection design, QSAR and virtual screening. He is the author of over 40 peer-reviewed scientific articles and reviews and is a named contributor on six patent applications.

Andrew Pannifer - University of Dundee, UK
Andrew is the computational chemist at the European Lead Factory.  He holds a B.A. (Biochemistry) and  D.Phil in Molecular Biophysics from Oxford University and has 10 years experience in the pharmaceutical industry, including 6 years in the Medicinal Informatics, Structure and Design Group at Pfizer, Sandwich.  In 2010, he established computational chemistry and crystallography at the Beatson Institute Drug Discovery Programme before moving to the European Lead Factory in July 2013.

David Brown - BT, UK
David is responsible for developing and implementing the technical vision of BT Global Service's health & life science set of offerings. David joined BT in 2006 and brings over 25 years of experience in the health and life science industries. Prior to joining BT David was a director of a company focused on providing disease management programmes in the areas of cardiovascular disease, diabetes, and oncology. Prior to this, David held senior management positions in various companies including PwC, GSK and Digital Equipment Company. David Brown gained a degree in medical science in 1981.

Yves Collenot - Sanofi-Aventis, France
Yves is an IS Project Leader at Sanofi-Aventis R&D, Montpellier. Initially specialized in the field of scientific imaging, he now leads IT projects for various Sanofi-Aventis R&D units.

Adrian Stevens - Accelrys, UK
Adrian is the Senior Product Marketing Manager for Discovery Studio, Accelrys’ premier Life sciences modelling and simulation product. He has more than 12 years experience in the practical application of computational chemistry; the vast majority of this time spent directly within the pharmaceutical industry (BioFocus DPI [part of Galapagos NV] and most recently, KuDOS Pharmaceuticals [part of AstraZeneca]).

Adrian received his PhD in Computational Chemistry from the University of Portsmouth in 1996, and subsequently continued in a post doctoral position under the direction of the late Prof. Martyn Ford. This work focused on the novel application of molecular spectra as descriptors to model drug activity.

Dr Stevens has published approximately 20 papers and is named on 3 patents. Publication topics have ranged from early work looking at optimising the design and synthesis of inorganic zeolites, through to more recent work which has focused on the development of in silico techniques to optimise drug design for key protein targets including kinases and G-protein coupled receptors. As well as having presented numerous papers at international conferences (as far afield as Japan), Dr Stevens has been actively involved in the computational science community, both in the organisation and support of conferences (such as the original “Cutting Edge Approaches to Drug Design” series, and in the “Young Modellers Forum”) and has been a past member of the Royal Society of Chemistry’s Molecular Modelling Group.

Rob Brown - Senior Director of Life Sciences Marketing, Accelrys, US
In this role Rob is responsible for the cheminformatics, bioinformatics and modelling and simulation products for the Life Sciences industries. He has been with Accelrys, MSI and SciTegic for 15 years involved in the product direction of the Pipeline Pilot and Informatics product lines Prior to MSI, Rob was a member of the Computer Aided Molecular Design group at Abbott Laboratories. Rob received his PhD in Cheminformatics from the University of Sheffield, UK under the direction of Prof Peter Willett.


Browse By: